Multi-wavelength diagnostics of accretion in an X-ray selected sample of CTTSs

High resolution X-ray spectroscopy has revealed soft X-rays from high density plasma in Classical T-Tauri stars (CTTSs), probably arising from the accretion shock region. However, the mass accretion rates derived from the X-ray observations are consistently lower than those derived from UV/optical/NIR studies. We aim to test the hypothesis that the high density soft X-ray emission is from accretion by analysing optical accretion tracers from an X-ray selected sample of CTTSs in a homogeneous manner. We analyse optical spectra of a sample of CTTSs and calculate the accretion rates based on measuring optical emission lines. These are then compared to the accretion rates derived from the X-ray spectroscopy. We find that, for each CTTS in our sample, the different optical tracers predict mass accretion rates that agree within the errors, albeit with a spread of ~1 order of magnitude. Typically, mass accretion rates derived from Halpha and HeI 5876 Ang are larger than those derived from Hbeta, Hgamma and OI. When comparisons of the optical mass accretion rates are made to the X-ray derived mass accretion rates, we find that: a) the latter are always lower (but by varying amounts); b) the latter range within a factor of ~2 around 2x10^{-10} M_odot yr^{-1}, despite the fact that the former span a range of ~3 orders of magnitude. We suggest that the systematic underestimation of the X-ray derived mass accretion rates could depend on the density distribution inside the accretion streams, where the densest part of the stream is not visible in the X-ray band because of the absorption by the stellar atmosphere. We also suggest that a non-negligible optical depth of X-ray emission lines produced by post-shock accreting plasma may explain the almost constant mass accretion rates derived in X-rays if the effect is larger in stars with larger optical mass accretion rates.Comment: 12 pages, 4 figures. Accepted for publication by A&

Magnetic fields and accretion flows on the classical T Tauri star V2129 Oph

From observations collected with the ESPaDOnS spectropolarimeter, we report the discovery of magnetic fields at the surface of the mildly accreting classical T Tauri star V2129 Oph. Zeeman signatures are detected, both in photospheric lines and in the emission lines formed at the base of the accretion funnels linking the disc to the protostar, and monitored over the whole rotation cycle of V2129 Oph. We observe that rotational modulation dominates the temporal variations of both unpolarized and circularly polarized line profiles. We reconstruct the large-scale magnetic topology at the surface of V2129 Oph from both sets of Zeeman signatures simultaneously. We find it to be rather complex, with a dominant octupolar component and a weak dipole of strengths 1.2 and 0.35 kG, respectively, both slightly tilted with respect to the rotation axis. The large-scale field is anchored in a pair of 2-kG unipolar radial field spots located at high latitudes and coinciding with cool dark polar spots at photospheric level. This large-scale field geometry is unusually complex compared to those of non-accreting cool active subgiants with moderate rotation rates. As an illustration, we provide a first attempt at modelling the magnetospheric topology and accretion funnels of V2129 Oph using field extrapolation. We find that the magnetosphere of V2129 Oph must extend to about 7R* to ensure that the footpoints of accretion funnels coincide with the high-latitude accretion spots on the stellar surface. It suggests that the stellar magnetic field succeeds in coupling to the accretion disc as far out as the corotation radius, and could possibly explain the slow rotation of V2129 Oph. The magnetospheric geometry we derive produces X-ray coronal fluxes typical of those observed in cTTSs.Comment: MNRAS, in press (18 pages, 17 figures

Analysis of the dust evolution in the circumstellar disks of TTauri stars

We present a compositional analysis of 8-13um spectra of 32 young stellar objects (YSOs). Our sample consists of 5 intermediate-mass stars and 27 low-mass stars. While the spectra and first scientific results have already been published by Przygodda et al. (2003) and Kessler-Silacci et al. (2004) we perform a more detailed analysis of the 10um silicate feature. In our analysis we assume that this emission feature can be represented by a linear superposition of the wavelength-dependent opacity $\kappa_{\rm abs}(\lambda)$ describing the optical properties of silicate grains with different chemical composition, structure, and grain size. The determination of an adequate fitting equation is another goal of this study. Using a restricted number of fitting parameters we investigate which silicate species are necessary for the compositional fitting. Particles with radii of 0.1um- and 1.5um consisting of amorphous olivine and pyroxene, forsterite, enstatite, and quartz have been considered. Only compact, homogeneous dust grains have been used in the presented fitting procedures. In this context we show that acceptable fitting results can also be achieved if emission properties of porous silicate grains are considered instead. Although some previous studies give reasons for the similarity between the dust in circumstellar disks of TTauri stars and Herbig Ae/Be stars, a quantitative comparison has been missing, so far. Therefore, we conclude with a discussion of the results of a 10um spectroscopic survey of van Boekel et al. (2005) who focus on Herbig Ae/Be stars, the higher mass counterparts of T Tauri stars and draw comparisons to this and other studies. We find that the results of our study of T Tauri systems partly agree with previous studies of Herbig Ae/Be stars.Comment: 17 pages, 6 figure

Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients

Vast transcriptomics and epigenomics changes are characteristic of human cancers, including leukaemia. At remission, we assume that these changes normalise so that omics-profiles resemble those of healthy individuals. However, an in-depth transcriptomic and epigenomic analysis of cancer remission has not been undertaken. A striking exemplar of targeted remission induction occurs in chronic myeloid leukaemia (CML) following tyrosine kinase inhibitor (TKI) therapy. Using RNA sequencing and whole-genome bisulfite sequencing, we profiled samples from chronic-phase CML patients at diagnosis and remission and compared these to healthy donors. Remarkably, our analyses revealed that abnormal splicing distinguishes remission samples from normal controls. This phenomenon is independent of the TKI drug used and in striking contrast to the normalisation of gene expression and DNA methylation patterns. Most remarkable are the high intron retention (IR) levels that even exceed those observed in the diagnosis samples. Increased IR affects cell cycle regulators at diagnosis and splicing regulators at remission. We show that aberrant splicing in CML is associated with reduced expression of specific splicing factors, histone modifications and reduced DNA methylation. Our results provide novel insights into the changing transcriptomic and epigenomic landscapes of CML patients during remission. The conceptually unanticipated observation of widespread aberrant alternative splicing after remission induction warrants further exploration. These results have broad implications for studying CML relapse and treating minimal residual disease

Abdominal ultrasonography in HIV/AIDS patients in southwestern Nigeria

<p>Abstract</p> <p>Background</p> <p>Though the major target of the HIV-virus is the immune system, the frequency of abdominal disorders in HIV/AIDS patients has been reported to be second only to pulmonary disease. These abdominal manifestations may be on the increase as the use of antiretroviral therapy has increased life expectancy and improved quality of life. Ultrasonography is an easy to perform, non invasive, inexpensive and safe imaging technique that is invaluable in Africa where AIDS is most prevalent and where sophisticated diagnostic tools are not readily available. Purpose: To describe the findings and evaluate the clinical utility of abdominal ultrasonography in HIV/AIDS patients in Ibadan, Nigeria</p> <p>Methods</p> <p>A Prospective evaluation of the abdominal ultrasonography of 391 HIV-positive patients as well as 391 age and sex-matched HIV-negative patients were carried out at the University College Hospital, Ibadan.</p> <p>Results</p> <p>Of the 391 cases studied, 260 (66.5%) were females; the mean age was 38.02 years, (range 15–66 years). The disease was most prevalent in the 4th decade with an incidence of 40.4%. Compared with the HIV-negative individuals, the HIV+ group of patients had a significantly higher proportion of splenomegaly (13.5% vs. 7.7%; p < 0.01), lymphadenopathy (2.0% vs. 1.3%; p < 0.70), and renal abnormalities (8.4% vs. 3.8%; p < 0.02). There were no differences in hepatic and pancreatic abnormalities between the HIV+ and HIV- groups. There were significantly fewer gallstones in the HIV+ group (1.4% vs. 5.1%; p < 0.01).</p> <p>Conclusion</p> <p>AIDS is a multi-systemic disease and its demographic and clinical pattern remains the same globally. Ultrasonography is optimally suited for its clinical management especially in Africa. Its accuracy and sensitivity may be much improved with clinico-pathologic correlation which may not be readily available in developing countries; further studies may provide this much needed diagnostic algorithms.</p

Primary Extracranial Meningiomas: An Analysis of 146 Cases

Primary extracranial meningiomas are rare neoplasms, frequently misdiagnosed, resulting in inappropriate clinical management. To date, a large clinicopathologic study has not been reported. One hundred and forty-six cases diagnosed between 1970 and 1999 were retrieved from the files of the Armed Forces Institute of Pathology. Histologic features were reviewed, immunohistochemistry analysis was performed (n = 85), and patient follow-up was obtained (n = 110). The patients included 74 (50.7%) females and 72 (49.3%) males. Tumors of the skin were much more common in males than females (1.7:1). There was an overall mean age at presentation of 42.4 years, with a range of 0.3–88 years. The overall mean age at presentation was significantly younger for skin primaries (36.2 years) than for ear (50.1 years) and nasal cavity (47.1 years) primaries. Symptoms were in general non-specific and reflected the anatomic site of involvement, affecting the following areas in order of frequency: scalp skin (40.4%), ear and temporal bone (26%), and sinonasal tract (24%). The tumors ranged in size from 0.5 up to 8 cm, with a mean size of 2.3 cm. Histologically, the majority of tumors were meningothelial (77.4%), followed by atypical (7.5%), psammomatous (4.1%) and anaplastic (2.7%). Psammoma bodies were present in 45 tumors (30.8%), and bone invasion in 31 (21.2%) of tumors. The vast majority were WHO Grade I tumors (87.7%), followed by Grade II (9.6%) and Grade III (2.7%) tumors. Immunohistochemically, the tumor cells labeled for EMA (76%; 61/80), S-100 protein (19%; 15/78), CK 7 (22%; 12/55), and while there was ki-67 labeling in 27% (21/78), <3% of cells were positive. The differential diagnosis included a number of mesenchymal and epithelial tumors (paraganglioma, schwannoma, carcinoma, melanoma, neuroendocrine adenoma of the middle ear), depending on the anatomic site of involvement. Treatment and follow-up was available in 110 patients: Biopsy, local excision, or wide excision was employed. Follow-up time ranged from 1 month to 32 years, with an average of 14.5 years. Recurrences were noted in 26 (23.6%) patients, who were further managed by additional surgery. At last follow-up, recurrent disease was persistent in 15 patients (mean, 7.7 years): 13 patients were dead (died with disease) and two were alive; the remaining patients were disease free (alive 60, mean 19.0 years, dead 35, mean 9.6 years). There is no statistically significant difference in 5-year survival rates by site: ear and temporal bone: 83.3%; nasal cavity: 81.8%; scalp skin: 78.5%; other sites: 65.5% (P = 0.155). Meningiomas can present in a wide variety of sites, especially within the head and neck region. They behave as slow-growing neoplasms with a good prognosis, with longest survival associated with younger age, and complete resection. Awareness of this diagnosis in an unexpected location will help to avoid potential difficulties associated with the diagnosis and management of these tumors

Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies

Cisplatin may have additive activity with temozolomide due to ablation of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (MGMT). This phase I/II study determined recommended combination doses using the Continual Reassessment Method, toxicities and antitumour activity in paediatric patients, and evaluated MGMT in peripheral blood mononuclear cells (PBMCs) in order to correlate with haematological toxicity. In total, 39 patients with refractory or recurrent solid tumours (median age ∼13 years; 14 pretreated with high-dose chemotherapy, craniospinal irradiation, or having bone marrow involvement) were treated with cisplatin, followed the next day by oral temozolomide for 5 days every 4 weeks at dose levels 80 mg m−2/150 mg m−2 day−1, 80/200, and 100/200, respectively. A total of 38 patients receiving 113 cycles (median 2, range 1–7) were evaluable for toxicity. Dose-limiting toxicity was haematological in all but one case. Treatment-related toxicities were thrombocytopenia, neutropenia, nausea-vomiting, asthenia. Hearing loss was experienced in five patients with prior irradiation to the brain stem or posterior fossa. Partial responses were observed in two malignant glioma, one brain stem glioma, and two neuroblastoma. Median MGMT activity in PBMCs decreased after 5 days of temozolomide treatment: low MGMT activity correlated with increased severity of thrombocytopenia. Cisplatin–temozolomide combinations are well tolerated without additional toxicity to single-agent treatments; the recommended phase II dosage is 80 mg m−2 cisplatin and 150 mg m−2 × 5 temozolomide in heavily treated, and 200 mg m−2 × 5 temozolomide in less-heavily pretreated children

The ATHENA X-ray Integral Field Unit (X-IFU)

The X-ray Integral Field Unit (X-IFU) is the high resolution X-ray spectrometer of the ESA Athena X-ray observatory. Over a field of view of 5' equivalent diameter, it will deliver X-ray spectra from 0.2 to 12 keV with a spectral resolution of 2.5 eV up to 7 keV on ∼ 5" pixels. The X-IFU is based on a large format array of super-conducting molybdenum-gold Transition Edge Sensors cooled at ∼ 90 mK, each coupled with an absorber made of gold and bismuth with a pitch of 249 μm. A cryogenic anti-coincidence detector located underneath the prime TES array enables the non X-ray background to be reduced. A bath temperature of ∼ 50 mK is obtained by a series of mechanical coolers combining 15K Pulse Tubes, 4K and 2K Joule-Thomson coolers which pre-cool a sub Kelvin cooler made of a 3He sorption cooler coupled with an Adiabatic Demagnetization Refrigerator. Frequency domain multiplexing enables to read out 40 pixels in one single channel. A photon interacting with an absorber leads to a current pulse, amplified by the readout electronics and whose shape is reconstructed on board to recover its energy with high accuracy. The defocusing capability offered by the Athena movable mirror assembly enables the X-IFU to observe the brightest X-ray sources of the sky (up to Crab-like intensities) by spreading the telescope point spread function over hundreds of pixels. Thus the X-IFU delivers low pile-up, high throughput (< 50%), and typically 10 eV spectral resolution at 1 Crab intensities, i.e. A factor of 10 or more better than Silicon based X-ray detectors. In this paper, the current X-IFU baseline is presented, together with an assessment of its anticipated performance in terms of spectral resolution, background, and count rate capability. The X-IFU baseline configuration will be subject to a preliminary requirement review that is scheduled at the end of 2018